200633-37-0Relevant academic research and scientific papers
Sulfonamide hybrid schiff bases of anthranilic acid: Synthesis, characterization and their biological potential
Kausar, Naghmana,Muratza, Shahzad,Raza, Muhammad Asam,Rafique, Hummera,Arshad, Muhammad Nadeem,Altaf, Ataf Ali,Asiri, Abdullah M.,Shafqat, Syed Salman,Shafqat, Syed Rizwan
, p. 8 - 20 (2019/03/14)
In the present work, the novel Schiff bases (03–20) of 4-chloro-N-[2-(hydrazinocarbonyl) phenyl]benzenesulfonamide (02) were synthesized by reacting it with various aldehydes. 4-Chloro-N-[2-(hydrazinocarbonyl) phenyl]benzenesulfonamide (02) was synthesize
Synthesis, structural analysis and pharmacological screening of chlorinated sulfonamides
Aziz-Ur-Rehman,Tahir, Saif-Ur-Rehman,Abbasi, Muhammad Athar,Rasool, Shahid,Siddiqa, Asia,Awais-Ur-Rehman,Muhammad, Ali,Sharif, Ahsan
, p. 9000 - 9004 (2013/11/19)
In present work, a facile and environmentally benign series of chlorinated sulfonamides was synthesized and screened against different enzymes. These were geared up by the coupling of 4-chlorobenzenesulfonyl chloride (1) with different substituted aromatic amines (2a-l) under dynamic pH control in aqueous media to form various chlorinated sulfonamides (3a-l). The synthesized chlorinated sulfonamides were spectrally characterized like 1H NMR, IR and EI-MS. The bioactivity of all the synthesized compounds were evaluated against urease, butyrylcholinesterase (BChE) and lipoxygenase (LOX) enzymes and found to be having talented activity against butyrylcholinesterase enzyme.
NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME
-
Page/Page column 34, (2010/04/03)
The present invention relates to a novel class of compounds comprising formula I, wherein n is 0 or 1. A is NR1, O, or S, wherein R1 is H, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, alkenyl, aryl, alkylaryl or arylalkyl. X is a carboxylate, a phosphonate, or a phosphate residue, or a C1-C10 alkyl residue optionally substituted with a carboxylate, phosphonate or phosphate residue. Y is a C1-C20 alkyl, alkenyl, halide, hydroxyl, C1-C20 alkoxy, aryl, alkylaryl, arylalkyl, cycloalkyl, cycloalkenyl, or a heterocyclic ring and is optionally substituted with one or more halides. Z is a H, a hydroxyl group, a halide, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, a cycloalkenyl group or a heterocyclic ring and is optionally substituted with one or more C1-C10 alkyl groups, C1-C10alkoxy groups, hydroxyl groups, cyano groups, carboxylate groups, halides, aryl groups, alkylaryl groups, arylalkyl groups, cycloalkyl groups, cycloalkenyl groups or heterocyclic rings.
Design and synthesis of small molecule glycerol 3-phosphate acyltransferase inhibitors
Wydysh, Edward A.,Medghalchi, Susan M.,Vadlamudi, Aravinda,Townsendd, Craig A.
experimental part, p. 3317 - 3327 (2010/03/26)
The incidence of obesity and other diseases associated with an increased triacylglycerol mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series has led to the identification of several compounds, in particular 2-(nonylsulfonamido)benzoic acid (15g), possessing moderate GPAT inhibitory activity in an intact mitochondrial assay.
